Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30957331 | 0.81 | GPR35 (0.41) | TSHRTDP1GPR35SMN1; SMN2MAPT | |
| SCHEMBL20741601 | 0.78 | TSHR (0.49) | TSHRTDP1SMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL1265167 | 0.77 | TDP1 (0.54) | TSHRTDP1GPR35SMN1; SMN2MAPT | |
| SCHEMBL2651124 | 0.77 | TDP1 (0.54) | TSHRTDP1GPR35SMN1; SMN2MAPT | |
| SCHEMBL312392 | 0.76 | GPR35 (0.64) | TSHRTDP1GPR35SMN1; SMN2L3MBTL1 | |
| SCHEMBL29506396 | 0.76 | GPR35 (0.64) | TSHRTDP1GPR35SMN1; SMN2L3MBTL1 | |
| SCHEMBL30041946 | 0.76 | TSHR (0.74) | TSHRTDP1SMN1; SMN2MAPTCYP2C9 | |
| SCHEMBL2932050 | 0.76 | TSHR (0.74) | TSHRTDP1SMN1; SMN2MAPTCYP2C9 | |
| SCHEMBL28755195 | 0.76 | TDP1 (0.52) | TSHRTDP1GPR35SMN1; SMN2MAPT | |
| SCHEMBL14577245 | 0.76 | BCHE (0.47) | TSHRTDP1GPR35SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11555026-B2 | AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-01-17 | — | — | US | disclosed |
| US-20210017153-A1 | AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2021-01-21 | — | — | US | disclosed |
| US-20210017153-A1 | AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2021-01-21 | — | — | US | disclosed |
| US-10696650-B2 | AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10696650-B2 | AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2020-06-30 | — | — | US | disclosed |
| EP-3668496-A1 | AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| US-20190055218-A1 | AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2019-02-21 | — | — | US | disclosed |
| US-20190055218-A1 | AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2019-02-21 | — | — | US | disclosed |
| WO-2019036657-A1 | AHR INHIBITORS AND USES THEREOF | KYN THERAPEUTICS (US) | 2019-02-21 | — | — | WO | disclosed |
| EP-2441762-A1 | Potentiators of Glutamate Receptors | Eli Lilly and Company (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20090318481-A1 | Potentiators Of Glutamate Receptors | AICHER THOMAS DANIEL | 2009-12-24 | — | — | US | disclosed |
| US-7598423-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | ARRAY BIOPHARMA, INC. | 2008-06-12 | — | — | US | disclosed |
| EP-1817301-A1 | POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006057870-A1 | POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | disclosed |
| CN-1083843-C | 2-(aminomethyl)-3,4,7,-9-tetrahydro-2H-pyrano-[2,3-e] indol-8-ones and derivatives | AMERICAN HOME PROD (US) | 2002-05-01 | — | — | CN | disclosed |
| EP-0771801-B1 | Chromane derivatives | AMERICAN HOME PROD (US) | 1999-03-03 | — | — | EP | disclosed |
| US-5750556-A | REDUCING DOPAMINE SYNTHESIS AND RELEASE, SCHIZOPHRENIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-05-12 | — | — | US | disclosed |
| CN-1151989-A | 2-(aminomethyl)-3,4,7,-9-tetrahydro-2H-pyrano-[2,3-e] indol-8-ones and derivatives | AMERICAN HOME PROD (US) | 1997-06-18 | — | — | CN | disclosed |
| EP-0771801-A1 | Chromane derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | GRM1, GRIN1, GRM2 | TSHR 248/4885TDP1 4070/4885GPR35 110/4885 |
| US-11555026-B2 | AHR inhibitors and uses thereof | AHR, ARNT, AIPL1 | TSHR 1220/4885TDP1 3458/4885GPR35 133/4885 |
| US-20210017153-A1 | AHR INHIBITORS AND USES THEREOF | AHR, ARNT, AIPL1 | TSHR 1220/4885TDP1 3458/4885GPR35 133/4885 |
| US-20090318481-A1 | Potentiators Of Glutamate Receptors | GRIK1, GRIK2, GRIK4 | TSHR 480/4885TDP1 3666/4885GPR35 67/4885 |
| US-10696650-B2 | AHR inhibitors and uses thereof | AHR, ARNT, AIPL1 | TSHR 1220/4885TDP1 3458/4885GPR35 133/4885 |
| US-20190055218-A1 | AHR INHIBITORS AND USES THEREOF | AHR, ARNT, AIPL1 | TSHR 1220/4885TDP1 3458/4885GPR35 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.